Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Blood|2019Cited by 218
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)Ramón García‐Sánz, Carmen Martı́nez, Á. Rodríguez et al.|Annals of Oncology|2019Cited by 129
Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)Ramón García‐Sánz, Carmen Martı́nez, Anna Sureda et al.|Blood|2016Cited by 47